Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis

曲妥珠单抗 医学 乳腺癌 内科学 荟萃分析 肿瘤科 科克伦图书馆 癌症 临床试验
作者
Zongyu Li,Shangwen Guo,Hongxia Xue,Luying Li,Yong Guo,Shufeng Duan,Zhisong He
出处
期刊:Frontiers in Pharmacology [Frontiers Media SA]
卷期号:14 被引量:8
标识
DOI:10.3389/fphar.2023.1183514
摘要

Background: Clinical trials have shown that the use of trastuzumab deruxtecan (DS-8201) alone is expected to provide novel therapeutic options for HER2-low/positive patients. Nevertheless, there are some variations in the efficacy of trial results, with potential risks at the safety level. Most DS-8201 trials in HER2 advanced breast cancer (ABC) have been conducted in the form of small-sample nonrandomized controlled studies, resulting in a lack of validated indicators to evaluate the efficacy and safety of DS-8201. Thus, this meta-analysis aimed to pool the results of various trials of DS-8201 alone to explore the efficacy and safety of DS-8201 in patients with HER2-low/positive advanced breast cancer. Methods: Relevant studies were searched in seven databases, including Embase, PubMed, Web of Science, Cochrane Library, CNKI, VIP database and WanFang data, to collect single-arm studies on DS-8201 for HER2-low/positive ABC. MINORS was adopted for quality assessment and STATA 16.0 for data analysis. Results: Ten studies involving 1,108 patients were included in this meta-analysis. As for the tumor response rate, the pooled ORR and DCR of all studies reached 57% (95% CI: 47%-67%) and 92% (95% CI: 89%-96%) respectively, and the pooled ORRs of the HER2-low expression group and the HER2-positive expression group were 46% (95% CI: 35%-56%) and 64% (95% CI: 54%-74%). Only the low expression group achieved median survival time, with a pooled median PFS and median OS of 9.24 (95% CI: 7.54-10.94) months and 23.87 (95% CI: 21.56-26.17) months, respectively. The most common treatment-related adverse events from DS-8201 were nausea (all grades: 62%; ≥ grade III: 5%), fatigue (all grade: 44%; ≥ grade III: 6%), and alopecia (all grades: 38%; ≥ grade III: 0.5%). Drug-related interstitial lung disease or pneumonitis occurred in 13% of the 1,108 patients, with only a 1% incidence of AE ≥ grade III. Conclusion: The present study suggests that DS-8201 is effective and safe in the treatment of ABC with low or positive HER2 expression, providing additional relevant information for its clinical application. However, further strengthening of the pairs is needed, as well as more clinical studies to support individualized treatment. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023390316.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小和完成签到,获得积分10
刚刚
刚刚
刚刚
刚刚
空想家完成签到 ,获得积分10
刚刚
(∩_∩)完成签到,获得积分10
1秒前
万能图书馆应助emma采纳,获得10
1秒前
绿色的大嘴鸟完成签到 ,获得积分10
1秒前
1秒前
1秒前
wyfre发布了新的文献求助10
1秒前
cyp发布了新的文献求助10
2秒前
雷豪发布了新的文献求助10
2秒前
Lqian_Yu完成签到 ,获得积分10
2秒前
眼睛大雨筠应助茹果采纳,获得30
3秒前
南宫完成签到,获得积分10
3秒前
3秒前
xulei完成签到,获得积分10
5秒前
5秒前
地火丢发布了新的文献求助10
5秒前
6秒前
bhvgbvnhvnh完成签到,获得积分10
6秒前
罗实完成签到 ,获得积分10
7秒前
咳咳哼完成签到,获得积分10
7秒前
7秒前
研友_VZG7GZ应助小静采纳,获得10
8秒前
8秒前
失眠的汽车完成签到,获得积分10
9秒前
9秒前
猛猛读文献的胖子完成签到,获得积分10
9秒前
可靠幼旋应助More采纳,获得10
9秒前
9秒前
10秒前
QK发布了新的文献求助10
10秒前
研友_VZG7GZ应助123采纳,获得10
10秒前
KING关注了科研通微信公众号
11秒前
11秒前
xiaowu发布了新的文献求助10
12秒前
yar应助xulei采纳,获得10
12秒前
巴纳拉完成签到,获得积分10
12秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Mission to Mao: Us Intelligence and the Chinese Communists in World War II 600
The Conscience of the Party: Hu Yaobang, China’s Communist Reformer 600
Geochemistry, 2nd Edition 地球化学经典教科书第二版,不要epub版本 431
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3301083
求助须知:如何正确求助?哪些是违规求助? 2935899
关于积分的说明 8474945
捐赠科研通 2609497
什么是DOI,文献DOI怎么找? 1424770
科研通“疑难数据库(出版商)”最低求助积分说明 662108
邀请新用户注册赠送积分活动 646072